Neuropathy Clinical Trials

This study will see if an investigational drug called NYX-2925 can reduce the nerve pain in the legs and feet associated with painful diabetic peripheral neuropathy.

The purpose of this study is to compare the efficacy of BHV-4157 versus placebo on ataxia symptoms in subjects with spinocerebellar ataxia (SCA).

Trial Name: A study to investigate how safe and able to produce an effect in the body study drug VX-150 in patients with pain that typically begins in the feet or hand People with pain caused by Small Fiber Neuropathy are asked to participate in a research study being conducted ...

Northern California Research is conducting a study for diabetic peripheral neuropathy (DPN). DPN is a type of nerve damage that can occur if you have diabetes. This study is for men and women who are experiencing painful diabetic peripheral neuropathy in both lower extremities (legs). The specific events that result ...

The purpose of this study is to evaluate the effectiveness of empagliflozin as a complimentary treatment to people with type 1 diabetes.

This is an extension trial to ECU-NMO-301 trial. A maximum of 132 patients are planned to be enrolled in the ECU-NMO-301 trial. This extension trial will be open to all patients who have completed the ECU-NMO-301 trial and meet the eligibility criteria.

EudraCT Number 2013-001150-10 STUDY NUMBER: ECU-NMO-301 Neuromyelitis Optica (NMO) or NMO Spectrum Disorders (NMOSD), also known as Devic’s Disease, is a rare, severe disabling autoimmune inflammatory disorder of the central nervous system (CNS) that predominately affects the optic nerves and spinal cord, and is often characterized by a relapsing course. ...

The injection of study medication will be administered by ultrasound-guided needle placement following ankle block anesthesia. The study staff will telephone subjects at Week 1 postinjection and subjects will return to the clinic postinjection at Weeks 2, 4, 8, and 12 for study assessments.

Suffering from Diabetic Neuropathy? If you suffer from Diabetic Peripheral Neuropathy, also known as DPN, you may be interested in learning more about a research study of an investigational medication being conducted locally.

The objectives of the MEDIAN study are to evaluate the short-term and long-term safety and nutritional benefits of Metanx® versus placebo in subjects with mild to moderate diabetic peripheral neuropathy (DPN). Short-term effects will be evaluated during the first 16 weeks of treatment, and long-term effects will be evaluated over ...